SRI International To Conduct Preclinical Studies Of Cancer Drug For Taiwan Liposome Company

Published: Oct 03, 2006

MENLO PARK, Calif.--(BUSINESS WIRE)--SRI International, an independent nonprofit research and development organization, today announced it has signed an agreement with Taiwan Liposome Company (TLC), a biopharmaceutical company, to begin preclinical safety and toxicology studies of a new cancer drug developed by TLC. The studies will be conducted in support of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA).

Back to news